Janney Montgomery Scott analyst Ken Trbovich says today's Federal Circuit Court's decision "removed the final barrier holding back generic competitors to Acorda Therapeutics' Ampyra. As such, the analyst expects "nearly immediate" launch of generic competition that will "rapidly capture" more than 90% of Acorda's Ampyra prescription volume and lead to the loss of nearly all of Ampyra's revenues over the coming months. This has long been the worst case scenario for Acorda, Trbovich tells investors in a research note. He keeps a Neutral rating on the shares with a $20 fair value estimate. The stock in midday trading is down 23%, or $6.35, to $21.50.